









Markets
/
Stocks
/
nasdaq-skye
/

Skye Bioscience Inc

SKYE

0.819USD

+0.020+2.48%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

25.39MMarket Cap

LossP/E TTM



Skye Bioscience Inc

0.819

+0.020+2.48%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Skye Bioscience Inc

Currency: USD Updated: 2026-02-06

Key Insights

Skye Bioscience Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 148 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.71.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Skye Bioscience Inc's Score

Industry at a Glance

Industry Ranking

148 / 392

Overall Ranking

293 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Skye Bioscience Inc Highlights

StrengthsRisks

Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -0.63, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 20.09M shares, decreasing 25.52% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 882.78K shares of this stock.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

8.714

Target Price

+989.97%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Skye Bioscience Inc is 7.00, ranking 169 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.00

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.24

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Skye Bioscience Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Skye Bioscience Inc is 6.19, ranking 316 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.63, which is -1804.13% below the recent high of 10.76 and -715.92% above the recent low of -5.15.

Score

Industry at a Glance

Previous score

6.19

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 148/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Skye Bioscience Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 20.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

8.714

Target Price

+989.97%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Skye Bioscience Inc

SKYE

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Skye Bioscience Inc is 5.08, ranking 332 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.02 and the support level at 0.70, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.14

Change

-0.06

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.030

Sell

RSI(14)

38.298

Neutral

STOCH(KDJ)(9,3,3)

11.972

Oversold

ATR(14)

0.079

High Vlolatility

CCI(14)

-166.768

Sell

Williams %R

87.018

Oversold

TRIX(12,20)

-0.262

Sell

StochRSI(14)

23.957

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.864

Sell

MA10

0.939

Sell

MA20

0.964

Sell

MA50

1.015

Sell

MA100

1.600

Sell

MA200

2.332

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Skye Bioscience Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 62.68%, representing a quarter-over-quarter decrease of 5.18%. The largest institutional shareholder is The Vanguard, holding a total of 882.78K shares, representing 2.75% of shares outstanding, with 10.53% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

5AM Ventures

9.68M

Versant Ventures

2.01M

Baker Bros. Advisors LP

1.45M

Schonfeld Strategic Advisors LLC

1.19M

+8.14%

The Vanguard Group, Inc.

Star Investors

882.78K

+5.35%

Ensign Peak Advisors, Inc.

767.29K

Driehaus Capital Management, LLC

620.39K

Sphera Funds Management Ltd.

478.93K

-11.05%

Alyeska Investment Group, L.P.

456.16K

Millennium Management LLC

402.38K

-14.52%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Skye Bioscience Inc is 1.95, ranking 266 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.85. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.